FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to overcome such drug resistance. We es...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Impact Journals LLC
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171601/ |